The Food and Drug Administration (FDA) has approved CAR-T using B cell maturation antigen (BCMA) as a target in treating refractory/relapsed MM, primarily as a neoadjuvant or bridging treatment for patients preparing for hematopoietic stem cell transplantation (HSCT). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.